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Abstract
In this editorial, we treat the multi-drug-resistance of microorganisms such as Klebsiella pneumonia (Kp) and
Acinetobacter baumanii and the issues concerning the management of these infections. Diseases caused by
carbapenemase-resistant Kp (CR-Kp) represent an emerging threat worldwide due to high mortality rate and limited
therapeutic options. Consequently innovative therapies have been suggested for their treatment. Colistin- based
combinations are considered the milestone of the therapy for CR-Kp. They include meropenem+colistin, meropenem
+colistin+tigecycline, the double carbapenem+colistin, tigecycline+colistin, colistin+gentamicin and even colistin
+vancomycin. However, colistin use might be limited by its potential nephrotoxicity and resistance. Other antibiotic
combinations concern the tigecycline with gentamicin, fosfomycin with aminoglycoside and ertapenem with
meropenem.
Thus, the double carbapenem-regimen might be considered as a suitable therapy in those subjects in whom
previous antimicrobial combinations failed. New antibiotics such as ceftazidime-avibactam effective on CR-Kp and
ceftolozane-tazobactam active against XDR (Extensively Drug Resistant) Pseudomonas aeruginosa are now being
used in many countries. The mortality results to be lower in patients treated with antibiotic combinations than in
those who underwent monotherapy. Efforts should be made by the clinicians in order to limit the widespread of these
resistant microorganisms all over the world. Encouraging new solutions as bacteriophage therapy or biocides
currently does not seem the right choice.
Keywords: Multidrug-resistance; Klebsiella pneumoniae;
Acinetobacter baumannii; Innovative therapies; Colistin; Antibiotics
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Editorial
Infections caused by multidrug-resistant (MDR) Gram-negative
bacteria such as Acinetobacter baumannii and Klebsiella pneumoniae
constitute an important issue for establishing a correct and appropriate
therapy in patients suffering from diseases deriving from these
microorganisms, both in Intensive Care Units (ICUs) and in non-ICU
settings. Carbapenemase-producing klebsiella pneumoniae (CP-Kp) is
the most common microorganism involved in nosocomial infections
over the last years. Outbreaks due to KPC (K. pneumoniae-
carbapenemase) have been detected in many countries around the
world; indeed these infections have become endemic other than in
Europe also in United States, Israel, and China [1].
KPC is an important mechanism of resistance for an increasingly
wide range of Gram-negative bacteria and is no longer limited to K.
pneumoniae being present also in E. coli. The spread of carbapenem-
resistant Enterobacteriaceae (CRE) has become a major challenge
worldwide, with a high impact on both morbidity and mortality in
human as well as in livestock. Infections due to CP-Kp are associated
with a high mortality rate [2,3].
In addition to resistance to carbapenems, CRE have recently
developed resistance to colistin, the cornerstone of combination
therapy against these microorganisms, as well as to fluoroquinolones
and aminoglycosides [4,5]. Consequently the proper management of
these difficult-to-treat bacteria could be very important especially in
some settings such as ICUs, cardiology and transplant wards where
these infections play a crucial role.
There is evidence that combination therapies are more effective than
monotherapy against CRE; however, the best regimen including two or
more drugs has not been found yet [6]. In this challenging scenario,
unconventional therapies have been proposed over the last years
including colistin-based associations such as the double carbapenem
regimen with colistin, colistin in combination with tigecycline, colistin
plus gentamicin, colistin plus meropenem with or without tigecycline,
even colistin plus vancomycin as well as combinations without colistin
such as fosfomycin plus an aminoglycoside, tigecycline with
gentamicin and meropenem plus ertapenem [2,7]. Several regimens of
triple therapy are under consideration during the last years [8].
Anyway a double-carbapenem regimen has been shown to be
effective and safe [9]. The use of the double carpanem therapy (i.e.
different combinations of two carbapenems including ertapenem
together with one of other carbapenems such as imipenem,
meropenem or doripenem) has been found very useful showing a
marked synergism between the two antimicrobial agents and a strong
bactericidal effect compared with the single components [10]. In these
combinations ertapenem plays a crucial role because it acts as a suicide
inhibitor against the KPCs allowing other carbapenems to enter into
the cells deprived of carbapenemases and to exert easily their
antibacterial activity. Following this, at Academic Hospital of Sapienza
University of Rome (Italy), we evaluated through antibiotic kill studies
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the in vitro synergistic activity of meropenem plus ertapenem against
pandrug-resistant Klebsiella isolated from 14 patients with CP-Kp
infections who were successfully treated with a double-carbapenem
therapy (ertapenem and meropenem). These carbapenems alone
showed very high MIC values (between 128 and 256 mcg/ml) through
macrodilution method in cation–adjusted Muller-Hinton broth.
However their association induced both clinical (defervescence in 48
h) and microbiological (absence of growth in culture media after 48 h
of therapy) responses. In in vitro studies, combination treatment
exhibited higher bacterial killing than a single antibiotic, even in the
presence of high carbapenem MICs. This report suggests that the
double carbapenem regimen might be considered a promising option
in CP-Kp infections, especially in patients for whom colistin treatment
is inappropriate due to resistance or toxicity [11,12].
In any case, the addition of colistin seems to strongly increase the
antibacterial activity of carbapenem-associations even against colistin-
resistant bacteria [13].
A case of bloodstream infection due to pandrug-resistant K.
pneumoniae has been reported to be successfully treated with an
innovative regimen comprising a combination of colistin plus double
carbapenem (ertapenem and meropenem at sub-MIC values). In vitro
analysis showed the synergistic and bactericidal effect of this regimen
[8].
However the role of colistin in the setting of colistin-resistant strains
is still debated. Although considered as part of antimicrobial
combinations against CR-Kp, colistin use might be limited by its
potential nephrotoxicity and resistance; thus as stated before, colistin-
free unconventional approaches such as the double-carbapenem
regimen, have been recently proposed among innovative approaches as
a valid alternative therapeutic option in severe infections.
The antibiotic associations are resulted to be appropriate also for
Acinetobacter baumannii that does not produce KPC but oxacillinase.
Therapeutic options for this microorganism are severely limited by the
emergence of strains resistant to most antibiotics including
carbapenems. In fact an increasing incidence of carbapenem-resistance
has recently been reported among multidrug-resistant Acinetobacter
due also to the decreased membrane permeability towards antibiotics
and to the expression of active efflux pumps that excrete drugs. Yet this
pathogen is intrinsically resistant to ertapenem so that the double
carbapenem treatment is not suitable in this case. Consequently the
treatment of these infections represents a real challenge. As a matter of
facts, it has been reported that the association of colistin with
vancomycin and meropenem results to be effective in pediatric
patients from ICU with systemic infections by this MDR
microorganism [14].
The rationale of using colistin plus vancomycin is based on the
hypothesis that colistin increases the permeability of the outer
membrane, thereby enhancing the antibacterial activity of large sized
hydrophobic molecules, such as vancomycin, which are normally
excluded by the Gram-negative outer membrane. Thus, the membrane-
perturbing properties of colistin could allow vancomycin to reach its
periplasmic target at inhibitory concentrations [14,15]. However
clinical experience due to the use of these two nephrotoxic antibiotics
is still poor and it should be more carefully evaluated.
Hence it would be interesting to examine these actual innovative
therapies against MDR Gram-negative bacteria in order to estimate
their activity related to different pathologies so that suitable treatments
might be suggested. It has been reported that in monotherapy treated
individuals, the mortality results to be higher than in patients who
received combination treatments [7]. In severe infections such as those
due to MDR bacteria, the patient’s outcome and the mortality rate are
often related to the commonly administered antibiotic treatment
regimens.
With regard to patients who received combination treatments,
mortality varies depending on the kind of the association. For instance
in 51 patients receiving the tigecycline-colistin combination the
mortality ranged from 0 to 30% [7,16], in 15 patients treated with
tigecycline plus gentamicin this value was included between 0-50%
[2,7], in 25 individuals undergone treatments with a carbapenem-
colistin combination it ranged from 0-67% [17] and in 30 patients
receiving colistin plus gentamicin it was from 40 to 61% [2,18].
Regarding patients who were treated with monotherapy, the mortality
resulted to be higher (i.e. ranging from 7 to 80% for the gentamicin
treatment) [2,16,19].
Anyway it can be deduced that the double or triple therapy may be
considered a valid option for clinical cure and microbiological
eradication in individuals with serious diseases.
The availability of new drugs against CRE seems to be encouraging
for clinicians facing critically ill patients with systemic infections due
to carbapenem-resistant K. pneumoniae and A. baumannii; however,
certain data are still pending. New antibiotics such as ceftazidime-
avibactam effective on KPC (Klebsiella pneumoniae-carpapenemase)
and ceftolozane-tazobactam active against XDR (Extensively Drug
Resistant) Pseudomonas aeruginosa are now being used in many
countries [20-22]. These recently approved drugs have become
available for MDR bacteria even for those microorganisms resistant to
treatment regimens described so far. For instance ceftolozane-
tazobactam (c/t) was recently approved for the cure of complicated
intra-abdominal infections or urinary tract infections. Notably c/t
demonstrated activity against many MDR isolates of Pseudomonas
aeruginosa including carbapenem-resistant strains that do not produce
a carbapenemase [20].
Newly discovered molecular mechanisms explain how bacteria
manage to survive on antibiotic treatment and cause chronic and
recurrent infections. This is often due to a physiological state called
persistence where the bacteria are tolerant to multiple antibiotics.
Bacterial cells may then switch into persistence which can lead to a
dormant phase in a kind of hibernation. Afterwards the
microorganisms can resuscitate to cause relapsing infections at any
time after the treatment is abandoned. About this, it would be very
interesting to study the molecular methods that underlie this issue
[23].
Conclusions and Further Perspectives
The study of MDR Enterobacteriaceae, with particular emphasis on
carbapenem-resistant Klebsiella pneumoniae and Acinetobacter
baumannii should be focused on both phenotypic and genotypic
pattern of antibiotic resistance and on new and active therapeutic
regimens for a better understanding of the mechanism of antibiotic
resistance and for suggesting more effective antimicrobial treatments.
It has been reported that for infections due to KPC-producing K.
pneumoniae, treatment failure was more common among patients who
were treated with monotherapy than among those undergone
antibiotic combinations [24]. The use of colistin in monotherapy could
be a challenge even for individuals in whom this drug is effective due
to its low plasma concentration thereby implying an increase in the
Citation: Mascellino MT, De Angelis M, Oliva A (2017) Multi-Drug Resistant Gram-Negative Bacteria: Antibiotic-Resistance and New Treatment
Strategies. Diagn Pathol Open 2: e106. doi:10.4172/2476-2024.1000e106
Page 2 of 4
Diagn Pathol Open, an open access journal
ISSN:2476-2024
Volume 2 • Issue 1 • 1000e106
daily dose of the antibiotic with possible consequences due to colistin-
induced nephrotoxicity. Innovative therapies are then advocated. The
double carbapenem regimen alone or in combination with colistin
even in patients yielding a colistin-resistant microorganism, the
associations of tygecycline with colistin, fosfomycin with an
aminoglycoside, a carbapenem or the colistin with an aminoglycoside
and even colistin plus vancomycin, have been referred as antibiotic
combinations effectively administered to patients infected with
carbapenemase-producing Enterobacteriaceae [25]. Synergy studies in
vitro correlated to clinical effectiveness, are a potential benefit arising
from the use of antibiotic combinations. These associations might also
prevent the occurrence of resistant strains during therapy and result in
lower mortality in critically ill patients with Klebsiella-KPC infections
[26]. The mortality rate results to be higher in a critical care setting
(above 60%) than in non-ICU patients (below 50%) for the same
antibiotic treatment either combination therapy or monotherapy [6].
The most common genotypic patterns of carbapenemases-
producing Klebsiella spp such as KPC, metallo-β-lactamase and
oxacillinase in various geographical areas, should be carefully taken
into account.
Among the KPCs, the KPC2 and KPC3 are currently the most
widespread variants whereas in the mid-90s only KPC1 was detected.
The most frequent KPCs result to be the sequence types ST258 and
ST512 belonging to the group KPC3 [27].
New emerging multi-resistant microorganisms other than K.
pneumoniae and A. baumannii (i.e. Enterobacter spp, E. coli, Proteus
spp, Ps. aeruginosa) are appearing in the current scenario worsening
the present situation. Molecular investigations should be then
conducted in order to identify the involved genes.
In conclusion, the multi-resistance is becoming an increasingly
problem in the last decade that requires a drastic intervention for
limiting the further widespread of resistant bacteria. New recently
approved drugs such as ceftazidime-avibactam effective on KPC and
ceftolozane-tazobactam effective on XDR Ps. aeruginosa, can be
considered as a rescue treatment for these infections.
Alternatively new therapeutic programs other than antibiotics could
be possibly taken into account such as some anti-bacterial
experimental treatments taking advantage of medicinal oils,
antibodies, common biocides [28], killing factors, drugs with
antibacterial activity different from antibiotics and even phage therapy
[29]. In the latter case a specific bacteriophage against a particular
microorganism (i.e. MDR Klebsiella pneumoniae or Acinetobacter
baumannii) could be used in order to lyse and kill the bacterium
infected by the phage. Unlike the antibiotics, in this situation no
resistance occurs. The limit of phage therapy, inherent in the
bacteriophage nature, lies in a narrow spectrum of action that on one
hand ensures high specificity and the absence of side-effects, on the
other hand needs the absolute knowledge of the infection etiologic
agent. The process that is on the basis of phage therapy, is complex
requiring an efficient laboratory for isolating a strictly specific
pathogen bacteriophage against the bacterium responsible of the
infection. Phage therapy firstly employed by the microbiologist Felix-
d’Herelle, was successfully adopted in clinical practice in eastern
countries, but it has been completely abandoned by western countries
[29].
All in all, it would be therefore highly recommended for clinicians
to make every effort to limit the widespread of the MDR bacteria all
over the world in order to avoid that the carbapenemases can become a
“every day” as well as the ESBL (extended spectrum β-lactamases).
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